Comparison of bypassing agents in bleeding reduction in treatment of bleeding episodes in patients with haemophilia and inhibitors

Iranian Red Crescent Medical Journal
Mina GolestaniAli Imani

Abstract

Mild-to-moderate bleeding disorders in haemophilia are primarily treated via recombinant activated factor VII a (rFVIIa) or activated prothrombin complex concentrate (aPCC). However, the efficacy of each bypassing agents may vary and none of them is universally effective. After reviewing the databases of PubMed, Scopus, MD Consult, Ovid, Trip database, Google Scholar, ProQuest and the Cochrane Library, finally, 17 papers published from 2000 to 2013 were extracted. We used as a random effect model in meta-analysis. Comprehensive meta-analysis (CMA) software was used for calculating and estimating the mean of bleeding reduction and performing meta-analysis. The mean of bleeding reduction in aPCC and rFVIIa were 71.2% with CI 95% (lower limit 86.8% and upper limit 82%) and 72.3% with CI 95% (lower limit 57.6% and upper limit 83.4%), respectively. Although differences between the two products were very close to each other, they reported similar effects on joint bleeds. Further clinical studies should be performed by incorporating a standardized measurement in comparative efficacy of aPCC and rFVIIa.

References

Dec 22, 1999·Haemophilia : the Official Journal of the World Federation of Hemophilia·C A Leissinger
Aug 30, 2002·Haemophilia : the Official Journal of the World Federation of Hemophilia·E P Mauser-BunschotenUNKNOWN Recombinant Factor VIIa Data Collection Group
Jun 28, 2003·Haemophilia : the Official Journal of the World Federation of Hemophilia·M Lloyd JonesC Knight
Jun 28, 2003·Haemophilia : the Official Journal of the World Federation of Hemophilia·C KnightM L Jones
Sep 24, 2004·Haemophilia : the Official Journal of the World Federation of Hemophilia·M Quintana-MolinaF Hernández-Navarro
Oct 14, 2004·Haemophilia : the Official Journal of the World Federation of Hemophilia·K Mulder, A Llinás
Apr 7, 2005·Haemophilia : the Official Journal of the World Federation of Hemophilia·R ParameswaranUNKNOWN HTRS Registry Investigators
May 7, 2005·Haemophilia : the Official Journal of the World Federation of Hemophilia·K G PutnamJ Avorn
Jul 13, 2006·Haemophilia : the Official Journal of the World Federation of Hemophilia·D Dimichele, C Négrier
Sep 21, 2007·Haemophilia : the Official Journal of the World Federation of Hemophilia·M C OzeloM Karamalis
Aug 30, 2008·Haemophilia : the Official Journal of the World Federation of Hemophilia·C W YouS K Park
Nov 20, 2008·Haemophilia : the Official Journal of the World Federation of Hemophilia·E Berntorp
Jan 22, 2009·Advances in Therapy·Chris KnightTessa Kennedy-Martin
Feb 4, 2009·Haemophilia : the Official Journal of the World Federation of Hemophilia·C KnightT Kennedy-Martin
Mar 27, 2009·Haemophilia : the Official Journal of the World Federation of Hemophilia·P A HolmeG E Tjønnfjord
Oct 23, 2009·Haemophilia : the Official Journal of the World Federation of Hemophilia·M N D Di MinnoA Coppola
Mar 1, 2010·Archives of Medical Science : AMS·Peyman EshghiMohammad Aghighi

❮ Previous
Next ❯

Software Mentioned

Google Scholar
SPSS
Ovid
Trip
Scopus
MD
ProQuest
consult
Comprehensive meta - analysis ( CMA )

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.